vs. Aurobindo Pharma Ltd.
Payout Range
Varies
Deadline
6/2/2026
Time Left
1 day
Aurobindo Pharma Ltd., Aurobindo Pharma USA, and Aurolife Pharma have agreed to a $2 million class action settlement to resolve claims that they manufactured and sold irbesartan blood pressure drugs contaminated with NDEA, a probable human carcinogen. This settlement is part of a larger multidistrict litigation concerning contamination in generic sartan medications, and it specifically addresses economic loss claims related to the defective drug.
No specific eligibility requirements listed. Review the official settlement terms for complete criteria.
U.S. consumers who paid for Aurobindo IC ROS irbesartan from January 1, 2016 to the present.
This settlement has the following claim path.
Payments will be made pro rata based on the amount spent on Aurobindo irbesartan during the class period.
This settlement accepts online and mail claim submissions. Pick whichever is easier.
Sartan Medication Settlement Administrator P.O. Box 3376 Baton Rouge, LA 70821
ClaimHawk is an independent service. Review the official settlement site for legally binding terms.